• 1
    Griffiths J. R., Cady E., Edwards R. H. T. McCready V. R., Wilkie D. R. and Wiltshaw E. 31P-NMR studies of a human tumour in situ. Lancet i, 143143 (1983).
  • 2
    Nidecker A. C., Müller S., Aue W. P., Seelig J., Fridrich R., Remagen W., Hartweg H. and Bentz U. F. Extremity bone tumors: evaluation by P-31 MR spectroscopy. Radiology 157, 16174 (1985).
  • 3
    Just M., Gutjahr P., Juretschke H. P., Dittrich M., Higer H. P., Klose K. J. and Ritter G. 31Phosphorspektroskopie bei osteogenem Sarkom; Möglichkeiten der Therapiekontrolle imm Vergleich mit bildgebenden Verfahren. Fortschr. Röontgenstr. 146, 14148 (1987).
  • 4
    Ross B., Helsper J. T., Cox I. J., Young I. R., Kempf R., Makepeace A. and Pennock J. Osteosarcoma and other neoplasms of bone; magnetic resonance spectroscopy to monitor therapy. Arch. Surg. 122, 146146 (1987).
  • 5
    Bryant D. J., Bydder G. M., Case H. A., Collins A. G., Cox I. J., Makepeace A. and Pennock J. M. Use of phosphorus-31 MR spectroscopy to monitor response to chemotherapy in non-Hodgkin lymphoma. J. Comput. Assist. Tomogr. 12, 77774 (1988).
  • 6
    Semmler W., Gademan G., Schlag P., Bachert-Baumann P., Zabel H. J., Lorenz W. J. and von Kaick G. Impact of hyperthermic regional perfusion therapy on cell metabolism of malignant melanoma monitored by 31P MR spectroscopy. Magn. Reson. Imag. 6, 3334 (1988).
  • 7
    Semmler W., Gademan G., Bachert-Baumann P., Zabel H. J., Lorenz W. J. and von Kaick G. Monitoring human tumor response to therapy by means of 31P MR spectroscopy. Radiology 166, 5353 (1988).
  • 8
    Lenkinski R. E., Listerud J., Shinkwin M. A., Zladkin M. B., Kressel H. Y., Schmidt R. G. and Daly J. M. Magnetic resonance imaging and magnetic resonance spectroscopy of bone tumors and bone marrow disease. Invest. Radiol. 12, 100101 (1989).
  • 9
    Redmond O. M., Stack J. P., Dervan P. A., Hurson B. J., Carney D. N. and Ennis J. T. Osteosarcoma: use of MR imaging and MR spectroscopy in clinical decision making. Radiology 172, 81815 (1989).
  • 10
    Negendank W. G., Crowley M. G., Ryan J. R., Keller N. A. and Evelhoch J. L. Bone and soft tissue lesions: diagnosis with combined H-1 MR imaging and P-31 MR spectroscopy. Radiology 173, 181181 (1989).
  • 11
    Koutcher J. A., Ballon D., Graham M., Healy J. H., Casper E. S., Heelan R. and Gerwick L. E. 31P NMR spectra of extremity sarcomas: diversity of metabolic profiles and changes in response to chemotherapy. Magn. Reson. Med. 16, 1634 (1990).
  • 12
    Dewhirst M. W., Sostman H. D., Leopold K., Charles H. C., Moore D., Burn R. A., Tucker J. A., Harrolson J. M. and Oleson J. Softtissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Radiology 174, 847853 (1990).
  • 13
    Sostman H. D., Charles H. C., Rockwell S., Leopold K., Beam C., Madwed D., Dewhirst M., Cofer G., Moore D., Burn R. and Oleson J. Soft-tissue sarcomas: detection of metabolic heterogeneity with P-31 MR spectroscopy. Radiology 176, 837843 (1990).
  • 14
    Zlatkin M. B., Lenkinski R. E., Shinkwin M., Schmidt R. G., Daly J. M., Holland G. A., Frank T. and Kressel H. Y. Combined MR imaging and spectroscopy of bone and soft tissue tumors. J. Comput. Assist. Tomogr. 14, 110 (1990).
  • 15
    Shinkwin M. A., Lenkinski R. E., Daly J. M., Zlatkin M. B., Frank T. S., Holland G. A. and Kressel H. Y. Integrated magnetic resonance imaging and phosphorus spectroscopy of soft tissue tumors. Cancer 67, 18491858 (1991).
  • 16
    Redmond O. M., Bell E., Stack J. P., Dervan P. A., Carney D. N., Hurson B. and Ennis J. T. Tissue characterization and assessment of preoperative chemotherapeutic response in muskuloskeletal tumors by in vivo 31P magnetic resonance spectroscopy. Magn. Reson. Med. 27, 226237 (1992).
  • 17
    Hoekstra H. J., Boeve W. J., Kamman R. L. and Mooyaart E. L. Clinical applicability of human in vivo localized phosphorus-31 magnetic resonance spectroscopy of bone and soft tissue tumors. Ann. Surg. Oncol. 1, 504511 (1994).
  • 18
    Prescott D. M., Charles H. C., Sostman D. H., Dodge R. K., Thrall D. E., Page R. L., Tucker J. A., Harrelson J. M., Leopold K. A., Oleson J. R. and Dewhirst M. W. Therapy monitoring in human and canine soft tissue sarcomas using magnetic resonance imaging and spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 28, 415423 (1994).
  • 19
    Vogl Th. J., von Wicklede M., Hohenberger P., Hochmuth K., Schlag P. and Felix R. Monitoring tumor response after isolated limb perfusion by means of 31P MR spectroscopy. Proceedings of the 3rd Annual Meeting of the Society of Magnetic Resonance. p. 1715 (1995).
  • 20
    Sijens P. E., Eggermont A. A. M. van Dijk P. and Oudkerk M. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by by single-dose TNF-α + Melphalan isolated limb perfusion. NMR Biomed. 8, 215224 (1995).
  • 21
    Möller H. E., Vermathen P., Rummeny E., Wörtler K., Wuisman P., Rössner A., Wörmann B., Ritter J. and Peters P. E. In vivo 31P NMR spectroscopy of human muskoskeletal tumors as a measure of response to chemotherapy. NMR Biomed. 9, 347358 (1996).
  • 22
    Wehrle J. P. and Glickson J. D. 31P NMR spectroscopy of tumors in vivo. Cancer Biochem. Biophys. 8, 1516 (1986).
  • 23
    Griffiths J. R., Bhujwalla Z., Coombes R. C., Maxwell R. J., Midwoood C. J., Morgan R. J., Nias A. H. W. Perry P., Prior M., Prysor-Jones R. A., Rodrigues L. M., Stubbs M. and Tozer G. M. Monitoring cancer therapy by NMR spectroscopy. N. Y. Acad. Sci. 4, 183199 (1987).
  • 24
    Daly P. F. and Cohen J. S. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res. 49, 770779 (1989).
  • 25
    Steen R. G. Response of solid tumors to chemotherapy monitored by in vivo 31P nuclear magnetic resonance spectroscopy: a review. Cancer Res. 49, 40754085 (1989).
  • 26
    Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5, 303324 (1992).
  • 27
    De Certaines J. D., Larsen V. A., Podo F., Carpinelli G., Briot O. and Henriksen O. Studies of human tumors by MRS: a review. NMR Biomed. 6, 345365 (1993).
  • 28
    Brown T. R., Kincaid B. M. and Ugurbil K. NMR chemical shift imaging in three dimensions. Proc. Natl Acad. Sci. USA 79, 35233526 (1982).
  • 29
    Sauter R., Müller S. and Weber H. Localization in vivo 31P NMR spectroscopy by combining surface coils and slice selective saturation. J. Magn. Reson. 75, 167173 (1987).
  • 30
    Ordidge R. J., Connelly A. and Lohman J. A. B. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson. 66, 283294 (1986).
  • 31
    Evanochko W. T., Sakai T. T., Ng T. C., Krishna N. R., Kim H. D., Zeidler R. B., Ghanta V. K., Brockman R. W., Schiffer L. M., Braunschweiger P. G. and Glickson J. D. NMR studies of in vivo RIF-1 tumors. Analysis of perchloric acid extracts and identification of 1H, 31P and 13C resonances. Biochim. Biophys. Acta 805, 104116 (1984).
  • 32
    Sostman D., Rockwell S., Smith G. J. W. Gore J. C., Kennedy K. A., Habib A., Fischer J. J., Armitage I. M. and Holcomb W. Magnetic resonance, pathology and physiology of the BA1112 rhabdomyosarcoma in vivo. Invest. Radiol. 23 277288 (1988).
  • 33
    Sijens P. E., van Echteld C. J. A., Neijt J. P., Schipper J., Dunki Jacobs, P. B., De Graaf P. W. and Seijkens D. 31P NMR study of the impact of dietary manipulation on tumor metabolism and response to methotrexate. NMR Biomed. 2, 1218 (1989).
  • 34
    Stubs M., Rodrigues L. M. and Griffiths J. R. Growth studies of subcutaneous rat tumours: comparison of 31P-NMR spectroscopy, acid extracts and histology. Br. J. Cancer 60, 701707 (1989).
  • 35
    Negendank W. G., Padavic-Shaller K. A., Li C. W., Murphy-Boesch B., Stoyanova R., Krigel R. L., Schilder R. J., Smith M. R. and Brown T. R. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 55, 32863294 (1995).
  • 36
    Evelhoch J. L., Bissery M.-C., Chabot G. G., Simpson N. E., McCoy C. L., Heilbrun L. K. and Corbett T. H. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48, 47494755 (1988).
  • 37
    Li S.-J., Wehrle J. P., Rajan S. S., Steen R. G., Glickson J. D. and Hilton J. Response of radiation-induced fibrosarcoma-1 in mice to cyclophosphamide monitored by in vivo 31P nuclear magnetic resonance spectroscopy. Cancer Res. 48, 473474 (1988).
  • 38
    Ballinger J. R., Kang H., Sweeney C. A., Scott J. D., Croker B. P. and Scott K. N. P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Magn. Reson. Imag. 13, 877883 (1995).
  • 39
    Steen R. G., Tamargo R. J., McGovern K. A., Rajan S. S., Brem H., Wehrle J. P. and Glickson J. D. In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effect of tumor growth and treatment with 1, 3-bis(2-chlorethyl)-1-nitrosurea on tumor energetics and histology. Cancer Res. 48, 676681 (1988).
  • 40
    Steen R. G., Tamargo R. J., Brem H., Glickson J. D. and Wehrle J. P. In vivo 31P nuclear magnetic resonance spectroscopy of rat 9L gliosarcoma treated with BCNU: dose response of spectral changes. Magn. Reson. Med. 11, 258266 (1989).
  • 41
    Steen R. G. and Graham M. M. In vivo 31P nuclear magnetic resonance spectroscopy is sensitive to tumor hypoxia: perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU. NMR Biomed. 4, 117124 (1991).
  • 42
    Li S. J., Wehrle J. P., Glickson J. D., Kumar N. and Braunschweiger P. G. Tumor bioenergetics and blood flow in RIF-1 murine tumors treated with 5-fluorouracil. Magn. Reson. Med. 22, 4756 (1991).
  • 43
    Sijens P. E., Baldwin N. J. and Ng T. C. Multinuclear MR investigation of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn. Reson. Med. 19, 373385 (1991).
  • 44
    Tozer G. M., Bhujwalla Z. M., Griffiths J. R. and Maxwell R. J. Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following x-radiation. Int. J. Radiat. Oncol. Biol. Phys. 16, 155164, 1989.
  • 45
    Rajan S. S., Wehrle J. P., Li S.-J., Steen R. G. and Glickson J. D. 31P NMR spectroscopic study of bioenergetic changes in radiation-induced fibrosarcoma-1 after radiation therapy. NMR Biomed. 2 165171 (1989).
  • 46
    Majors A. W., Ng T. C., Karalis I. M., Edinger M. G., Tubbs R. R., Higgins P. D. and Shin K. H. Phosphorus metabolites and the distribution of cell cycle phase of RIF-1 tumors in response to 14 Gy irradiation. Magn. Reson. Med. 16, 425430 (1990).
  • 47
    Li S.-J., Jin G.-Y. and Moulder J. E. Effects of local irradiation on spin-lattice relaxation time of phosphate metabolites in mouse tumors monitored by 31P magnetic resonance spectroscopy. Magn. Reson. Med. 23, 302310 (1992).
  • 48
    Sijens P. E., Baldwin N. J. and Ng T. C. 31P magnetic resonance spectroscopy detection of response-predictive adenosine triphosphate decrease in irradiated radiation-induced fibrosarcoma-1 tumors. Invest. Radiol. 32, 3943 (1997).
  • 49
    Bremmer J. C. M. Bradley J. K., Stratford I. J. and Adams G. E. Magnetic resonance spectroscopic studies on ‘real-time’ changes in RIF-1 tumour metanolismand blood flow during and after photodynamic therapy. Br. J. Cancer 69, 10831087 (1994).
  • 50
    Matiello J., Evelhoch J. L., Brown E., Schaap A. P. and Hetzel F. W. Effect of photodynamic therapy on RIF-1 tumor metabolism and blood flow examined by 31P and 2H NMR spectroscopy. NMR Biomed. 2, 6470 (1992).
  • 51
    Koutcher J. A., Okunieff P., Neuringer L., Suit H. and Brady T. Size dependent changes in tumor phosphate metabolism after radiation therapy as detected by 31P NMR spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 13, 18551855 (1987).
  • 52
    Allavena C., Guerquin-Kern J.-L. and Lhoste J.-M. Follow-up by 31P NMR spectroscopy of the energy metabolism of malignant tumor in rats during treatment. Radiother. Oncol. 21, 4852 (1991).
  • 53
    Shine N., Palladino M. A., Patton Jr. J. S. Deisseroth A., Kacmar G. S., Matson G. B. and Weiner M. W. Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study. Cancer Res. 49, 21237 (1989).
  • 54
    Karczmar G. S., Speder A. and Weiner W. M. Acute effects of TNF on tumor metabolism and perfusion. Proceedings of the 8th Annual Meeting of the Society of Magnetic Resonance in Medicine. p. 147 (1989).
  • 55
    Karczmar G. S., Arbeit J. M., Toy B. J., Speder A. and Weiner M. W. Selective depletion of tumor NTP by 2-deoxyglucose and insulin, detected by 31P magnetic resonance spectroscopy. Cancer Res. 52, 7176, 1992.
  • 56
    Kluge M., Elger B., Engel T., Schaefer C., Seega J. and Vaupel P. Acute effect of tumor necrosis factor alpha or lymphotoxin on global blood flow, laser Doppler flux and bioenergetic status of subcutaneous rodent tumors. Cancer Res. 52, 216773 (1992).
  • 57
    Constantinides I., Braunschweiger P. G., Wehrle J. P., Kumar N., Johnson C. S., Furanski P. and Glickson J. D. 31P-Nuclear magnetic resonance studies of the effect of recombinant human interleukine 1α on the bioenergetics of RIF-1 tumors. Cancer Res. 48, 63796382 (1989).
  • 58
    Proietti E., Carpinelli G., Di Vito M., Belardelli F., Gresser I. and Podo F. 31P nuclear magnetic resonance analysis of interferoninduced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. Cancer Res. 46, 284957 (1986).
  • 59
    Podo F., Carpinelli G., Di Vito M., Giannini M., Proietti E., Fiers W., Gresser I. and Belardelli F. Nuclear magnetic resonance analysis of tumor necrosis factor-induced alterations of phospholipid metabolites and pH in Friend leukemia cell tumor and fibrosarcoma in mice. Cancer Res. 47, 64819 (1987).
  • 60
    Lilly M. B., Ng T. C., Evanochko W. T., Katholi C. R., Kumar N. G., Elgavish G. A., Durant J. R., Hiramoto R., Ghanta V. and Glickson J. D. Loss of high-energy phosphate following hyperthermia demonstrated by in vivo 31P-nuclear magnetic resonance spectroscopy. Cancer Res. 44, 633638 (1984).
  • 61
    Lilly M. B., Katholi C. R. and Ng T. C. Direct relationship between high-energy phosphate content and blood flow in thermally treated murine tumors. J. Natl Cancer Inst. 75, 885889 (1985).
  • 62
    Gadian D. G. Magnetic resonance spectroscopy as a probe of tumour metabolism. Eur. J. Cancer 27, 526528 (1991).
  • 63
    Naruse S., Hirakawa K., Horikawa Y., Tanaka C., Higuchi T., Ueda S., Nishikawa H. and Watari H. Measurements of in vivo 31P nuclear magnetic resonance spectra in neuroectodermal tumors for the evaluation of the effects of chemotherapy. Cancer Res. 45, 24292433 (1985).
  • 64
    Wehrle J. P., Li S.-J., Rajan S., Steen R. G. and Glickson J. D. 31P and 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy. Ann. N.Y. Acad. Sci. 508, 200215 (1987).
  • 65
    Sijens P. E., Bovee W. M. M. J., Koole P. and Schipper J. Phosphorus NMR study of the response of a murine mammary tumour to hyperthermia as a function of treatment time and temperature. Int. J. Hyperthermia 5, 351357 (1989).
  • 66
    Rofstad E. K. NMR spectroscopy in prediction and monitoring of radiation response of tumours in vivo. Int. J. Radiat. Biol. 57, 15 (1990).
  • 67
    Steen R. G. Characterization of tumor hypoxia by 31P MR spectroscopy. Am. J. Roentgenol. 157, 243248 (1991).
  • 68
    Koutcher J. A., Barnett D., Kornblith A. B., Cowburn D., Brady T. J. and Gerweck L. E. Relationship of in pH and energy status to hypoxic cell fraction an hyperthermia sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 18, 14291435 (1990).
  • 69
    Hoffer F. A., Taylor G. A., Spevak M., Ingber D. and Fenton T. Metabolism of tumor regression from angiogenesis inhibition: 31P magnetic resonance spectroscopy. Magn. Reson. Med. 11, 202208 (1988).
  • 70
    Tozer G. M. and Griffiths J. R. The contribution made by cell death and oxygenation to 31P MRS observations of tumour energy metabolism. NMR Biomed. 5, 27989 (1992).
  • 71
    Maris J. M., Evans A. E., McLaughlin A. C., D' Angio G. J., Bolinger L., Manos H. and Chance B. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. New Engl. J. Med. 312, 150005 (1985).
  • 72
    Ng T. C., Grundvest S., Vijayakumar S., Baldwin N. J., Majors A. W., Karalis I., Meaney T. F., Shin K. H., Thomas F. J. and Tubbs R. Therapeutic response of breast carcinoma monitored by 31P MRS in situ. Magn. Reson. Med. 10, 125134 (1989).
  • 73
    Schilling A., Gewiese B., Berger G., Boese-Landgraf J., Fobbe F., Stiller D., Gallkowski U. and Wolf K. J. Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization. Radiology 182, 88790 (1992).